Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 127Squamous Cell Carcinoma of Head and Neck 64Melanoma 64Parkinson Disease 4, Autosomal Dominant Lewy Body 53Lung Neoplasms 50Triple Negative Breast Neoplasms 47Neoplasm Metastasis 46Breast Neoplasms 42Neoplasms 38Colorectal Neoplasms 33Carcinoma, Renal Cell 30Head and Neck Neoplasms 28Endometrial Neoplasms 28Ovarian Neoplasms 27Carcinoma, Transitional Cell 23Urinary Bladder Neoplasms 21Stomach Neoplasms 17Pancreatic Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 13Brain Neoplasms 13Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Carcinoma, Squamous Cell 11Carcinoma, Hepatocellular 11Cholangiocarcinoma 10Skin Neoplasms 9Esophageal Squamous Cell Carcinoma 9

Interventions

Gemcitabine 6Cisplatin 6pembrolizumab 4durvalumab 3Oxaliplatin 3tivozanib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2trametinib 1tislelizumab 1olaparib 1atezolizumab 1Yttrium-90 1Stents 1Radiosurgery 1Nivolumab 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Floxuridine 1Dexamethasone 1Capecitabine 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × pembrolizumab × 90 days × Clear all
NCT04924062 2026-04-15

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
158 enrolled 19 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT05346484 2026-03-06

MAST

Imugene Limited

Phase 1 Terminated
66 enrolled
Gastrointestinal

Bile Duct Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡